Journal
JOURNAL OF CHEMICAL INFORMATION AND MODELING
Volume 61, Issue 9, Pages 4125-4130Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jcim.1c00903
Keywords
-
Categories
Funding
- NIH from NIGMS [R44GM122196-02A1]
- NCCAM [3R43AT010585-01S1]
- NIEHS [1R43ES031038-01]
Ask authors/readers for more resources
While a recent publication suggested that cationic amphiphilic drugs repurposed for COVID-19 may not be effective in vivo, additional experimental data supports the efficacy of many of these molecules both in vitro and in vivo without causing phospholipidosis. Therefore, further exploration of this class of compounds is warranted in the search for broad spectrum antivirals.
A recent publication in Science has proposed that cationic amphiphilic drugs repurposed for COVID-19 typically use phosholipidosis as their antiviral mechanism of action in cells but will have no in vivo efficacy. On the contrary, our viewpoint, supported by additional experimental data for similar cationic amphiphilic drugs, indicates that many of these molecules have both in vitro and in vivo efficacy with no reported phospholipidosis, and therefore, this class of compounds should not be avoided but further explored, as we continue the search for broad spectrum antivirals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available